Drug intelligence / Profile preview

mifepristone + antidepressant

Development stage
Phase 3
Lead developer
Corcept Therapeutics
Modality
Small Molecules
Administration
Oral
01

Overview

This is a **combination therapy** involving **mifepristone** and an **antidepressant**. Mifepristone is a synthetic steroid and a potent antagonist of the **glucocorticoid receptor** and **progesterone receptor**. While primarily approved and known for terminating pregnancy, it has also been studied for rapid treatment of **psychotic major depression**, especially in patients with elevated cortisol and poor response to conventional drugs[1][2][4][5]. Antidepressants, most commonly **selective serotonin reuptake inhibitors (SSRIs)**, are a diverse class of drugs whose members enhance serotonergic neurotransmission in the brain, primarily by inhibiting the serotonin transporter. In psychiatric research, mifepristone has been used adjunctively with antidepressants to achieve more rapid and robust reduction in psychotic and depressive symptoms in major depressive disorder with psychotic features[1][4][5]. No unique fixed-dose combination product is marketed under this name; rather, the combination refers to **concurrent use of mifepristone and an antidepressant** as part of a clinical regimen.

02

Targets

GR (Glucocorticoid receptor)PR (Progesterone receptor)SERT (Sodium-dependent serotonin transporter)

Beyond the preview

Go deeper on mifepristone + antidepressant.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on mifepristone + antidepressant.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call